The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras G12D acute myeloid leukemia

Oncogene

Volumn 32, Issue 7, 2013, Pages 930-938

  Shi, J ^a,b   Wang, E ^a,e   Zuber, J ^a,c   Rappaport, A ^a   Taylor, M ^a   Johns, C ^a   Lowe, S W ^a,d,e   Vakoc, C R ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

chromatin; epigenetics; leukemia; MLL; PRC2

Indexed keywords

POLYCOMB REPRESSIVE COMPLEX 2; SHORT HAIRPIN RNA; TUMOR SUPPRESSOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; HEMATOPOIETIC CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ANIMALS; ASPARTIC ACID; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENES, RAS; GLYCINE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MUTATION, MISSENSE; ONCOGENE PROTEINS, FUSION; POLYCOMB REPRESSIVE COMPLEX 2; POLYCOMB-GROUP PROTEINS; TUMOR CELLS, CULTURED;

EID: 84874106911     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.110     Document Type: Article

References (49)

1. Schuettengruber B, Martinez AM, Iovino N, Cavalli G. Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol 2011; 12: 799-814.
2. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10: 697-708.
3. Lewis EB. A gene complex controlling segmentation in Drosophila. Nature 1978; 276: 565-570.
4. Kennison JA, Tamkun JW. Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila. Proc Natl Acad Sci USA 1988; 85: 8136-8140.
5. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009; 9: 773-784.
6. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-1043.
7. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of Zeste protein. Genes Dev 2002; 16: 2893-2905.
8. Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002; 111: 197-208.
9. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008; 32: 491-502.
10. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129: 1311-1323.
11. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 2008; 4: e1000242.
12. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006; 441: 349-353.
13. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006; 125: 301-313.
14. Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, Hannon G et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 2009; 136: 1122-1135.
15. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
16. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117: 2451-2459.
17. Wigle TJ, Knutson SK, Jin L, Kuntz KW, Pollock RM, Richon VM et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett 2011; 585: 3011-3014.
18. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
19. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-667.
20. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995; 378: 505-508.
21. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7: 823-833.
22. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001; 20: 5695-5707.
23. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004; 80-97.
24. Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev 2009; 23: 877-889.
25. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
26. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The Menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005; 123: 207-218.
27. Maillard I, Chen YX, Friedman A, Yang Y, Tubbs AT, Shestova O et al. Menin regulates the function of hematopoietic stem cells and lymphoid progenitors. Blood 2009; 113: 1661-1669.
28. Tsai S, Bartelmez S, Sitnicka E, Collins S. Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development. Genes Dev 1994; 8: 2831-2841.
29. Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev 1994; 8: 1184-1197.
30. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J 2004; 23: 4061-4071.
31. Montgomery ND, Yee D, Chen A, Kalantry S, Chamberlain SJ, Otte AP et al. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol 2005; 15: 942-947.
32. Zuber J, McJunkin K, Fellmann C, Dow LE, Taylor MJ, Hannon GJ et al. Toolkit for evaluating genes required for proliferation and survival using tetracyclineregulated RNAi. Nat Biotechnol 2010; 29: 79-83.
33. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006; 10: 257-268.
34. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-822.
35. Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated selfrenewal program as essential for leukemia maintenance. Genes Dev 2011; 25: 1628-1640.
36. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, Fuchs U et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004; 24: 617-628.
37. Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009; 4: 129-140.
38. Nigten J, Breems-de Ridder MC, Erpelinck-Verschueren CA, Nikoloski G, van der Reijden BA, van Wageningen S et al. ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells. Leukemia 2005; 19: 799-805.
39. Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev 2000; 14: 704-718.
40. Hellborg F, Qian W, Mendez-Vidal C, Asker C, Kost-Alimova M, Wilhelm M et al. Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. Oncogene 2001; 20: 5466-5474.
41. Williams RT, Sherr CJ. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCRABL-induced leukemias. Cold Spring Harb Symp Quant Biol 2008; 73: 461-467.
42. Dickins RA, McJunkin K, Hernando E, Premsrirut PK, Krizhanovsky V, Burgess DJ et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet 2007; 39: 914-921.
43. Tan J, Jones M, Koseki H, Nakayama M, Muntean AG, Maillard I et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 2011; 20: 563-575.
44. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Vire E et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 2007; 11: 513-525.
45. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009; 114: 2733-2743.
46. Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury 3rd WJ et al. Role of the Polycomb protein EED in the propagation of repressive histone marks. Nature 2009; 461: 762-767.
47. Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A et al. A model for transmission of the H3K27me3 epigenetic mark. Nat Cell Biol 2008; 10: 1291-1300.
48. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
49. Mochizuki-Kashio M, Mishima Y, Miyagi S, Negishi M, Saraya A, Konuma T et al. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood 2011; 118: 6553-6561.